Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCCC NASDAQ:CLNN NASDAQ:EDIT NASDAQ:ELDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.98-0.2%$2.83$1.21▼$3.82$326.57M2.772.35 million shs512,161 shsCLNNClene$7.26-1.7%$5.82$2.28▼$13.50$85.58M0.89363,767 shs94,310 shsEDITEditas Medicine$3.13+3.1%$2.68$1.35▼$4.54$306.94M2.141.67 million shs343,330 shsELDNEledon Pharmaceuticals$3.98+3.0%$3.12$1.35▼$4.60$306.83M0.941.19 million shs406,064 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+1.71%+5.30%+8.76%+63.74%+99.33%CLNNClene+3.21%+19.97%+18.05%+72.26%+189.80%EDITEditas Medicine-4.42%+1.00%+10.58%+66.48%+127.82%ELDNEledon Pharmaceuticals+1.58%+6.04%+26.56%+76.26%+28.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCCCC4 Therapeutics$2.98-0.2%$2.83$1.21▼$3.82$326.57M2.772.35 million shs512,161 shsCLNNClene$7.26-1.7%$5.82$2.28▼$13.50$85.58M0.89363,767 shs94,310 shsEDITEditas Medicine$3.13+3.1%$2.68$1.35▼$4.54$306.94M2.141.67 million shs343,330 shsELDNEledon Pharmaceuticals$3.98+3.0%$3.12$1.35▼$4.60$306.83M0.941.19 million shs406,064 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCCCC4 Therapeutics+1.71%+5.30%+8.76%+63.74%+99.33%CLNNClene+3.21%+19.97%+18.05%+72.26%+189.80%EDITEditas Medicine-4.42%+1.00%+10.58%+66.48%+127.82%ELDNEledon Pharmaceuticals+1.58%+6.04%+26.56%+76.26%+28.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCCCC4 Therapeutics 2.57Moderate Buy$7.75160.50% UpsideCLNNClene 2.67Moderate Buy$33.25357.93% UpsideEDITEditas Medicine 2.57Moderate Buy$5.4072.80% UpsideELDNEledon Pharmaceuticals 2.40Hold$9.67143.19% UpsideCurrent Analyst Ratings BreakdownLatest CLNN, CCCC, EDIT, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.005/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026CLNNClene Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.003/12/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.003/10/2026EDITEditas Medicine JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.003/9/2026EDITEditas Medicine Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCCCC4 Therapeutics$35.95M9.12N/AN/A$2.65 per share1.12CLNNClene$200K427.67N/AN/A($1.62) per share-4.48EDITEditas Medicine$38.69M7.91N/AN/A$0.05 per share62.50ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCCCC4 Therapeutics-$104.99M-$1.36N/AN/AN/A-292.08%-53.83%-33.85%N/ACLNNClene-$26.17M-$2.60N/AN/AN/A-13,086.50%N/A-135.77%N/AEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%5/11/2026 (Estimated)ELDNEledon Pharmaceuticals-$45.62M-$0.52N/AN/AN/AN/A-85.61%-31.93%5/13/2026 (Estimated)Latest CLNN, CCCC, EDIT, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22N/AN/AN/AN/AN/A5/11/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million3/19/2026Q4 2025ELDNEledon Pharmaceuticals-$0.20-$0.10+$0.10-$0.10N/AN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million2/26/2026Q4 2025CCCCC4 Therapeutics-$0.43-$0.18+$0.25-$0.18$4.48 million$11.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCCCCC4 TherapeuticsN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCCCC4 TherapeuticsN/A7.817.81CLNNCleneN/A0.830.83EDITEditas MedicineN/A3.223.54ELDNEledon PharmaceuticalsN/A7.407.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCCCC4 Therapeutics78.81%CLNNClene23.28%EDITEditas Medicine71.90%ELDNEledon Pharmaceuticals56.77%Insider OwnershipCompanyInsider OwnershipCCCCC4 Therapeutics8.73%CLNNClene28.30%EDITEditas Medicine2.10%ELDNEledon Pharmaceuticals12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCCCC4 Therapeutics150110.18 million100.56 millionOptionableCLNNClene10011.78 million8.45 millionNo DataEDITEditas Medicine23097.91 million95.85 millionOptionableELDNEledon Pharmaceuticals1077.19 million67.69 millionOptionableCLNN, CCCC, EDIT, and ELDN HeadlinesRecent News About These CompaniesEledon Pharmaceuticals (ELDN) Expected to Announce Earnings on WednesdayMay 6 at 6:29 AM | marketbeat.comNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon ...April 30, 2026 | markets.businessinsider.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from AnalystsApril 21, 2026 | marketbeat.comHere is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your MoneyApril 20, 2026 | finance.yahoo.comWhy Eledon Pharmaceuticals, Inc.’s (ELDN) Stock Is Up 5.90%April 19, 2026 | aaii.comAEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 14.5% in MarchApril 17, 2026 | marketbeat.comSG Americas Securities LLC Makes New Investment in Eledon Pharmaceuticals, Inc. $ELDNApril 10, 2026 | marketbeat.comEledon Pharmaceuticals, Inc. Common Stock (ELDN)March 27, 2026 | nasdaq.comEledon Unveils New Type 1 Diabetes DataMarch 23, 2026 | ocbj.comOEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsMarch 20, 2026 | finanznachrichten.deEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsMarch 19, 2026 | globenewswire.comEledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive AlternativeMarch 16, 2026 | seekingalpha.comEledon Pharmaceuticals, Inc.: Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago MedicineMarch 16, 2026 | finanznachrichten.deEledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago MedicineMarch 16, 2026 | finance.yahoo.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationMarch 10, 2026 | finanznachrichten.deEledon Pharma rises on FDA orphan status for lead assetMarch 10, 2026 | msn.comEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationMarch 10, 2026 | globenewswire.comNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesMarch 9, 2026 | prnewswire.comEledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare ConferenceMarch 4, 2026 | globenewswire.comEledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 5, 2026 | globenewswire.comEledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter SymposiumJanuary 23, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThis AI Lender Has Big Upside Potential—And Big Risks By Peter Frank | April 19, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026Capital One’s Big Bet Faces Rising Credit RiskBy Peter Frank | May 6, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026CLNN, CCCC, EDIT, and ELDN Company DescriptionsC4 Therapeutics NASDAQ:CCCC$2.98 -0.01 (-0.17%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Clene NASDAQ:CLNN$7.26 -0.13 (-1.75%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Editas Medicine NASDAQ:EDIT$3.12 +0.10 (+3.14%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Eledon Pharmaceuticals NASDAQ:ELDN$3.98 +0.12 (+2.98%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
